Loading…
Association of serum MIP-1[alpha], MIP-1[beta], and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus
The aim of this study was to determine if macrophage inflammatory protein (MIP) 1α, MIP-1β, and RANTES (regulated upon activation normally T-cell expressed and secreted) serum concentrations are associated with clinical manifestations, disease activity, and damage accrual in patients with systemic l...
Saved in:
Published in: | Clinical rheumatology 2007-05, Vol.26 (5), p.718 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | |
container_end_page | |
container_issue | 5 |
container_start_page | 718 |
container_title | Clinical rheumatology |
container_volume | 26 |
creator | Vilá, Luis M Molina, María J Mayor, Angel M Cruz, José J Ríos-olivares, Eddy Ríos, Zilka |
description | The aim of this study was to determine if macrophage inflammatory protein (MIP) 1α, MIP-1β, and RANTES (regulated upon activation normally T-cell expressed and secreted) serum concentrations are associated with clinical manifestations, disease activity, and damage accrual in patients with systemic lupus erythematosus (SLE). A cross-sectional study was performed in 62 SLE patients (per American College of Rheumatology criteria) participating in a longitudinal study and 20 healthy subjects. MIP-1α, MIP-1β, and RANTES serum concentrations were determined by enzyme-linked immunosorbent assay. Demographic parameters, clinical manifestations, serologic features, pharmacologic treatments, disease activity, and damage accrual were determined at study visit. Disease activity was assessed with the Systemic Lupus Erythematosus Activity Measure (SLAM), and disease damage was assessed with Systemic Lupus International Collaborating Clinic Damage Index (SDI). The relation between the variables was studied with the Student t test and the Pearson r correlation test. SLE patients were more likely to have higher concentrations of MIP-1β and RANTES than healthy individuals. In addition, they had a trend to have higher concentrations of MIP-1α. Patients with discoid lupus were more likely to have higher levels of MIP-1α. Elevation of MIP-1β correlated with higher SDI score. No association was found between serum chemokines levels and disease activity. In conclusion, SLE patients have higher serum levels of MIP-1β and RANTES than healthy individuals. MIP-1α is associated with discoid lupus, and MIP-1β correlates with damage accrual in SLE. This study suggests that chemokines may have a role in the pathogenesis of SLE.[PUBLICATION ABSTRACT] |
doi_str_mv | 10.1007/s10067-006-0387-y |
format | article |
fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_881264588</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2417644881</sourcerecordid><originalsourceid>FETCH-proquest_journals_8812645883</originalsourceid><addsrcrecordid>eNqNjUFOwzAQRS0EEqFwAHYj1jXYTWicZYWKYAGqoDuEqsFxiKvEDhkblMNwV1LoAdj80f9_3gxj51JcSiHyKxp1nvNRuEhVzocDlsgszXhRZMUhS0SeC57KQh2zE6KtEGKmCpmw7wWR1xaD9Q58BWT62MLD_YrLF2y6Gl-ne_dmws6gK-Fp8bhePsOXDTXoxjqrsYEWna0Mhd9TNIXSkkEygDrYTxuGP7TEFt93oe7jCFkHNFAwrdXQxC4SmH4ItWkxeIp0yo4qbMic7eeEXdwu1zd3vOv9RxyfbbY-9m6sNkrJ2Ty7Vir919IPdxRgrA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>881264588</pqid></control><display><type>article</type><title>Association of serum MIP-1[alpha], MIP-1[beta], and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus</title><source>Springer Nature</source><creator>Vilá, Luis M ; Molina, María J ; Mayor, Angel M ; Cruz, José J ; Ríos-olivares, Eddy ; Ríos, Zilka</creator><creatorcontrib>Vilá, Luis M ; Molina, María J ; Mayor, Angel M ; Cruz, José J ; Ríos-olivares, Eddy ; Ríos, Zilka</creatorcontrib><description>The aim of this study was to determine if macrophage inflammatory protein (MIP) 1α, MIP-1β, and RANTES (regulated upon activation normally T-cell expressed and secreted) serum concentrations are associated with clinical manifestations, disease activity, and damage accrual in patients with systemic lupus erythematosus (SLE). A cross-sectional study was performed in 62 SLE patients (per American College of Rheumatology criteria) participating in a longitudinal study and 20 healthy subjects. MIP-1α, MIP-1β, and RANTES serum concentrations were determined by enzyme-linked immunosorbent assay. Demographic parameters, clinical manifestations, serologic features, pharmacologic treatments, disease activity, and damage accrual were determined at study visit. Disease activity was assessed with the Systemic Lupus Erythematosus Activity Measure (SLAM), and disease damage was assessed with Systemic Lupus International Collaborating Clinic Damage Index (SDI). The relation between the variables was studied with the Student t test and the Pearson r correlation test. SLE patients were more likely to have higher concentrations of MIP-1β and RANTES than healthy individuals. In addition, they had a trend to have higher concentrations of MIP-1α. Patients with discoid lupus were more likely to have higher levels of MIP-1α. Elevation of MIP-1β correlated with higher SDI score. No association was found between serum chemokines levels and disease activity. In conclusion, SLE patients have higher serum levels of MIP-1β and RANTES than healthy individuals. MIP-1α is associated with discoid lupus, and MIP-1β correlates with damage accrual in SLE. This study suggests that chemokines may have a role in the pathogenesis of SLE.[PUBLICATION ABSTRACT]</description><identifier>ISSN: 0770-3198</identifier><identifier>EISSN: 1434-9949</identifier><identifier>DOI: 10.1007/s10067-006-0387-y</identifier><language>eng</language><publisher>Heidelberg: Springer Nature B.V</publisher><subject>Autoimmune diseases ; Drug therapy ; Lupus</subject><ispartof>Clinical rheumatology, 2007-05, Vol.26 (5), p.718</ispartof><rights>Clinical Rheumatology 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Vilá, Luis M</creatorcontrib><creatorcontrib>Molina, María J</creatorcontrib><creatorcontrib>Mayor, Angel M</creatorcontrib><creatorcontrib>Cruz, José J</creatorcontrib><creatorcontrib>Ríos-olivares, Eddy</creatorcontrib><creatorcontrib>Ríos, Zilka</creatorcontrib><title>Association of serum MIP-1[alpha], MIP-1[beta], and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus</title><title>Clinical rheumatology</title><description>The aim of this study was to determine if macrophage inflammatory protein (MIP) 1α, MIP-1β, and RANTES (regulated upon activation normally T-cell expressed and secreted) serum concentrations are associated with clinical manifestations, disease activity, and damage accrual in patients with systemic lupus erythematosus (SLE). A cross-sectional study was performed in 62 SLE patients (per American College of Rheumatology criteria) participating in a longitudinal study and 20 healthy subjects. MIP-1α, MIP-1β, and RANTES serum concentrations were determined by enzyme-linked immunosorbent assay. Demographic parameters, clinical manifestations, serologic features, pharmacologic treatments, disease activity, and damage accrual were determined at study visit. Disease activity was assessed with the Systemic Lupus Erythematosus Activity Measure (SLAM), and disease damage was assessed with Systemic Lupus International Collaborating Clinic Damage Index (SDI). The relation between the variables was studied with the Student t test and the Pearson r correlation test. SLE patients were more likely to have higher concentrations of MIP-1β and RANTES than healthy individuals. In addition, they had a trend to have higher concentrations of MIP-1α. Patients with discoid lupus were more likely to have higher levels of MIP-1α. Elevation of MIP-1β correlated with higher SDI score. No association was found between serum chemokines levels and disease activity. In conclusion, SLE patients have higher serum levels of MIP-1β and RANTES than healthy individuals. MIP-1α is associated with discoid lupus, and MIP-1β correlates with damage accrual in SLE. This study suggests that chemokines may have a role in the pathogenesis of SLE.[PUBLICATION ABSTRACT]</description><subject>Autoimmune diseases</subject><subject>Drug therapy</subject><subject>Lupus</subject><issn>0770-3198</issn><issn>1434-9949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNqNjUFOwzAQRS0EEqFwAHYj1jXYTWicZYWKYAGqoDuEqsFxiKvEDhkblMNwV1LoAdj80f9_3gxj51JcSiHyKxp1nvNRuEhVzocDlsgszXhRZMUhS0SeC57KQh2zE6KtEGKmCpmw7wWR1xaD9Q58BWT62MLD_YrLF2y6Gl-ne_dmws6gK-Fp8bhePsOXDTXoxjqrsYEWna0Mhd9TNIXSkkEygDrYTxuGP7TEFt93oe7jCFkHNFAwrdXQxC4SmH4ItWkxeIp0yo4qbMic7eeEXdwu1zd3vOv9RxyfbbY-9m6sNkrJ2Ty7Vir919IPdxRgrA</recordid><startdate>20070501</startdate><enddate>20070501</enddate><creator>Vilá, Luis M</creator><creator>Molina, María J</creator><creator>Mayor, Angel M</creator><creator>Cruz, José J</creator><creator>Ríos-olivares, Eddy</creator><creator>Ríos, Zilka</creator><general>Springer Nature B.V</general><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20070501</creationdate><title>Association of serum MIP-1[alpha], MIP-1[beta], and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus</title><author>Vilá, Luis M ; Molina, María J ; Mayor, Angel M ; Cruz, José J ; Ríos-olivares, Eddy ; Ríos, Zilka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_8812645883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Autoimmune diseases</topic><topic>Drug therapy</topic><topic>Lupus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vilá, Luis M</creatorcontrib><creatorcontrib>Molina, María J</creatorcontrib><creatorcontrib>Mayor, Angel M</creatorcontrib><creatorcontrib>Cruz, José J</creatorcontrib><creatorcontrib>Ríos-olivares, Eddy</creatorcontrib><creatorcontrib>Ríos, Zilka</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vilá, Luis M</au><au>Molina, María J</au><au>Mayor, Angel M</au><au>Cruz, José J</au><au>Ríos-olivares, Eddy</au><au>Ríos, Zilka</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association of serum MIP-1[alpha], MIP-1[beta], and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus</atitle><jtitle>Clinical rheumatology</jtitle><date>2007-05-01</date><risdate>2007</risdate><volume>26</volume><issue>5</issue><spage>718</spage><pages>718-</pages><issn>0770-3198</issn><eissn>1434-9949</eissn><abstract>The aim of this study was to determine if macrophage inflammatory protein (MIP) 1α, MIP-1β, and RANTES (regulated upon activation normally T-cell expressed and secreted) serum concentrations are associated with clinical manifestations, disease activity, and damage accrual in patients with systemic lupus erythematosus (SLE). A cross-sectional study was performed in 62 SLE patients (per American College of Rheumatology criteria) participating in a longitudinal study and 20 healthy subjects. MIP-1α, MIP-1β, and RANTES serum concentrations were determined by enzyme-linked immunosorbent assay. Demographic parameters, clinical manifestations, serologic features, pharmacologic treatments, disease activity, and damage accrual were determined at study visit. Disease activity was assessed with the Systemic Lupus Erythematosus Activity Measure (SLAM), and disease damage was assessed with Systemic Lupus International Collaborating Clinic Damage Index (SDI). The relation between the variables was studied with the Student t test and the Pearson r correlation test. SLE patients were more likely to have higher concentrations of MIP-1β and RANTES than healthy individuals. In addition, they had a trend to have higher concentrations of MIP-1α. Patients with discoid lupus were more likely to have higher levels of MIP-1α. Elevation of MIP-1β correlated with higher SDI score. No association was found between serum chemokines levels and disease activity. In conclusion, SLE patients have higher serum levels of MIP-1β and RANTES than healthy individuals. MIP-1α is associated with discoid lupus, and MIP-1β correlates with damage accrual in SLE. This study suggests that chemokines may have a role in the pathogenesis of SLE.[PUBLICATION ABSTRACT]</abstract><cop>Heidelberg</cop><pub>Springer Nature B.V</pub><doi>10.1007/s10067-006-0387-y</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0770-3198 |
ispartof | Clinical rheumatology, 2007-05, Vol.26 (5), p.718 |
issn | 0770-3198 1434-9949 |
language | eng |
recordid | cdi_proquest_journals_881264588 |
source | Springer Nature |
subjects | Autoimmune diseases Drug therapy Lupus |
title | Association of serum MIP-1[alpha], MIP-1[beta], and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T04%3A33%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20of%20serum%20MIP-1%5Balpha%5D,%20MIP-1%5Bbeta%5D,%20and%20RANTES%20with%20clinical%20manifestations,%20disease%20activity,%20and%20damage%20accrual%20in%20systemic%20lupus%20erythematosus&rft.jtitle=Clinical%20rheumatology&rft.au=Vil%C3%A1,%20Luis%20M&rft.date=2007-05-01&rft.volume=26&rft.issue=5&rft.spage=718&rft.pages=718-&rft.issn=0770-3198&rft.eissn=1434-9949&rft_id=info:doi/10.1007/s10067-006-0387-y&rft_dat=%3Cproquest%3E2417644881%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_8812645883%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=881264588&rft_id=info:pmid/&rfr_iscdi=true |